FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377011716> ?p ?o ?g. }

• W4377011716 endingPage "1906" @default.
• W4377011716 startingPage "1905" @default.
• W4377011716 abstract "Retinopathy of prematurity (ROP) continues to threaten the vision of premature infants. Premature exposure to an environment that is richer in oxygen than the uterus stops, or even regresses, retinal vasculature. This induces the first avascular phase of ROP, as confirmed by rodent models of oxygen-induced retinopathy. The second proliferative phase is reactive hypoxia-induced neovascularisation. Clinicians use defensive strategies to reduce the occurrence or progression of ROP, by preventing preterm deliveries and providing minimal oxygen support during the first weeks of life. Pharmacological approaches are currently poor. However, our team explored using unselective Beta 1/2 adrenoceptor antagonist propranolol during the proliferative phase of oxygen-induced retinopathy. This significantly reduced hypoxia-induced retinal neovascularisation by counteracting hypoxia-inducible factor-1 upregulation and the downstream proangiogenic cascade.1 Explorative clinical trials and three meta-analyses2 showed that oral propranolol reduced ROP progression and the need for laser photocoagulation or anti-vascular endothelial growth factor treatment. However, this risked life-threatening complications in unstable preterm infants.3 Animal studies of oxygen-induced retinopathy,1 found that eye micro-drops with 0.1% or 0.2% propranolol were safe, but only the 0.2% formulation decreased ROP progression.4 This study in the Neonatal Intensive Care Unit of the University Hospital of Pisa, Italy, aimed to provide further data on the impact of propranolol eye micro-drops on infants with early stages ROP. The medical records of all very low birth weight (VLBW) infants, born weighing <1500 g, with any stage of ROP were evaluated. We compared progression in patients admitted in 2010–2018, when no pharmacologic treatment was available, with patients admitted in 2019–2022 and treated with propranolol 0.2% eye micro-drops. Propranolol administration was maintained until complete retinal vascularisation had been achieved or 90 days had elapsed. Ophthalmologists documented disease progression in both groups using the International Classification of ROP, Second Revision and recorded images using retinal cameras. The study was approved by the Pediatric Ethical Committee for Clinical Research, Tuscany region (number 52/2023), and informed consent was obtained from both parents. There were 94/415 VLBW infants (22.7%) with ROP in 2010–2018 and 27/134 (20.1%) in 2019–2022 (p = 0.544). We excluded 13 historic controls who had been enrolled in previous trials with propranolol and two from the treatment groups with late ROP stage 1. The final study comprised 81 historic controls born at a mean gestational age of 27.4 ± 2.4 weeks and 25 treated patients born at a mean of 26.4 ± 2.0 weeks. The treatment group had a significantly lower birthweight (p = 0.005), and a higher incidence of respiratory distress syndrome (p = 0.032). They were more likely to receive medication for patent ductus arteriosus (p = 0.024) and red blood cell transfusions (p = 0.027). Treated infants received three micro-drops of propranolol 0.2% (6 μL in each eye) every 6 h, delivered using a micropipette, followed by the compression of the nasolacrimal duct for 30 s. Just over a third (36%) began treatment when they had stage 1 ROP, while the others (64%) began it at stage 2. The average duration of treatment was 52.1 ± 21.5 days. No interruptions were reported. No difference was observed in the progression to stage 2 ROP. However, there was a fourfold reduction in the number of treated infants who reached stage 3 when the treatment and control groups were compared (p = 0.013). The number needed to treat was 2.7 (95% confidence interval 1.761–6.215). A trend towards a reduction was also observed in the progression to stages 2–3 plus and to stage 4 (Figure 1). No adverse events were attributed to propranolol, namely severe hypotension, bradycardia, apnoea, bronchospasm, hypoglycaemia, local signs or rebound after treatment discontinuation. Our study confirmed that 0.2% eye propranolol micro-drops were effective in breaking the link between hypoxia and vascular proliferation in ROP, although the results were probably underestimated. On the one hand, the start of treatment could be more uniformly anticipated at ROP stage 1, potentially reinforcing its efficacy. On the other hand, the groups compared in this study were not perfectly homogeneous, suggesting that the beneficial effects were obtained in a population with a higher risk of severe ROP. This secondary prevention approach is safe, very inexpensive and easily available and the absence of undesirable effects make it a useful tool for decreasing the progression of ROP. Importantly, this makes it suitable for even low-income countries. Retinopathy of prematurity is predominantly considered a proliferative vascular disease. However, persistent vision impairments due to photoreceptors and post-receptor retinal neuron disorders observed in patients who had ROP suggest associations with neurosensory alterations.5 Therefore, the availability of a drug with high cerebrospinal fluid permeability that interrupts the progression of ROP, protects retinal cells and prevents astrocyte degeneration5 could provide neuroprotection. Our study produced interesting results, but had some limitations. The treated cohort number was too low to draw definitive conclusions and higher doses of propranolol might increase treatment efficacy, without prejudicing safety and tolerability. The way that eye micro-drops are administered is not specifically designed for this purpose. Caregivers need training to administer the drug with acceptable accuracy and a more user-friendly system could ensure better results. Finally, retrospective, non-blinded studies may present bias and prospective randomised controlled trials are needed. In conclusion, this study showed that treating infants with 0.2 propranolol eye micro-drops drastically reduced the progression of retinopathy of prematurity, but more studies are needed. None. None." @default.
• W4377011716 created "2023-05-19" @default.
• W4377011716 creator A5002007850 @default.
• W4377011716 creator A5003313642 @default.
• W4377011716 creator A5004254624 @default.
• W4377011716 creator A5056180095 @default.
• W4377011716 creator A5057831734 @default.
• W4377011716 creator A5063256188 @default.
• W4377011716 creator A5063314751 @default.
• W4377011716 creator A5073860524 @default.
• W4377011716 creator A5077538925 @default.
• W4377011716 creator A5091971062 @default.
• W4377011716 date "2023-05-24" @default.
• W4377011716 modified "2023-09-27" @default.
• W4377011716 title "Treating infants with 0.2% propranolol eye micro‐drops drastically reduced the progression of retinopathy of prematurity" @default.
• W4377011716 cites W2071871591 @default.
• W4377011716 cites W2943850039 @default.
• W4377011716 cites W3127271732 @default.
• W4377011716 cites W4206394351 @default.
• W4377011716 doi "https://doi.org/10.1111/apa.16850" @default.
• W4377011716 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37199226" @default.
• W4377011716 hasPublicationYear "2023" @default.
• W4377011716 type Work @default.
• W4377011716 citedByCount "0" @default.
• W4377011716 crossrefType "journal-article" @default.
• W4377011716 hasAuthorship W4377011716A5002007850 @default.
• W4377011716 hasAuthorship W4377011716A5003313642 @default.
• W4377011716 hasAuthorship W4377011716A5004254624 @default.
• W4377011716 hasAuthorship W4377011716A5056180095 @default.
• W4377011716 hasAuthorship W4377011716A5057831734 @default.
• W4377011716 hasAuthorship W4377011716A5063256188 @default.
• W4377011716 hasAuthorship W4377011716A5063314751 @default.
• W4377011716 hasAuthorship W4377011716A5073860524 @default.
• W4377011716 hasAuthorship W4377011716A5077538925 @default.
• W4377011716 hasAuthorship W4377011716A5091971062 @default.
• W4377011716 hasBestOaLocation W43770117161 @default.
• W4377011716 hasConcept C118487528 @default.
• W4377011716 hasConcept C134018914 @default.
• W4377011716 hasConcept C178790620 @default.
• W4377011716 hasConcept C185592680 @default.
• W4377011716 hasConcept C187212893 @default.
• W4377011716 hasConcept C2777091541 @default.
• W4377011716 hasConcept C2778151854 @default.
• W4377011716 hasConcept C2778313320 @default.
• W4377011716 hasConcept C2778376644 @default.
• W4377011716 hasConcept C2779234561 @default.
• W4377011716 hasConcept C2779918416 @default.
• W4377011716 hasConcept C2780827179 @default.
• W4377011716 hasConcept C42219234 @default.
• W4377011716 hasConcept C540031477 @default.
• W4377011716 hasConcept C54355233 @default.
• W4377011716 hasConcept C555293320 @default.
• W4377011716 hasConcept C71924100 @default.
• W4377011716 hasConcept C7836513 @default.
• W4377011716 hasConcept C86803240 @default.
• W4377011716 hasConceptScore W4377011716C118487528 @default.
• W4377011716 hasConceptScore W4377011716C134018914 @default.
• W4377011716 hasConceptScore W4377011716C178790620 @default.
• W4377011716 hasConceptScore W4377011716C185592680 @default.
• W4377011716 hasConceptScore W4377011716C187212893 @default.
• W4377011716 hasConceptScore W4377011716C2777091541 @default.
• W4377011716 hasConceptScore W4377011716C2778151854 @default.
• W4377011716 hasConceptScore W4377011716C2778313320 @default.
• W4377011716 hasConceptScore W4377011716C2778376644 @default.
• W4377011716 hasConceptScore W4377011716C2779234561 @default.
• W4377011716 hasConceptScore W4377011716C2779918416 @default.
• W4377011716 hasConceptScore W4377011716C2780827179 @default.
• W4377011716 hasConceptScore W4377011716C42219234 @default.
• W4377011716 hasConceptScore W4377011716C540031477 @default.
• W4377011716 hasConceptScore W4377011716C54355233 @default.
• W4377011716 hasConceptScore W4377011716C555293320 @default.
• W4377011716 hasConceptScore W4377011716C71924100 @default.
• W4377011716 hasConceptScore W4377011716C7836513 @default.
• W4377011716 hasConceptScore W4377011716C86803240 @default.
• W4377011716 hasIssue "9" @default.
• W4377011716 hasLocation W43770117161 @default.
• W4377011716 hasLocation W43770117162 @default.
• W4377011716 hasOpenAccess W4377011716 @default.
• W4377011716 hasPrimaryLocation W43770117161 @default.
• W4377011716 hasRelatedWork W1991151698 @default.
• W4377011716 hasRelatedWork W2004228627 @default.
• W4377011716 hasRelatedWork W2070322992 @default.
• W4377011716 hasRelatedWork W2123374335 @default.
• W4377011716 hasRelatedWork W2127045213 @default.
• W4377011716 hasRelatedWork W2165748990 @default.
• W4377011716 hasRelatedWork W2780688356 @default.
• W4377011716 hasRelatedWork W3213250623 @default.
• W4377011716 hasRelatedWork W4220709707 @default.
• W4377011716 hasRelatedWork W4284701438 @default.
• W4377011716 hasVolume "112" @default.
• W4377011716 isParatext "false" @default.
• W4377011716 isRetracted "false" @default.
• W4377011716 workType "article" @default.